StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) stock

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.86−0.10 (-2.53%)

Close on Nov 17, 2026Market cap $188.72MP/E –Yield –

Artiva Biotherapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Artiva Biotherapeutics's price to sales ratio was 10.4× on Jan 31, 2025.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jan 31, 202510.4×−10.3
2024Dec 31, 202420.7×–

More Artiva Biotherapeutics figures

See a number that looks wrong?